title: Treatments of clinical mastitis occurring in cows on 51 large dairy herds in Wisconsin.
abstract: Antimicrobials are frequently used for treatment of bovine mastitis and few studies have examined modern treatment strategies on large US dairy farms. The objective of this study was to describe treatment practices for clinical mastitis occurring in cows on large dairy herds in Wisconsin. Treatments performed on 747 cows experiencing cases of mild, moderate, or severe symptoms of clinical mastitis were recorded on 51 Wisconsin dairy farms. Duplicate milk samples were collected from the affected quarter for microbiological analysis at the onset of clinical mastitis and 14 to 21 d after treatment ended. Cows were treated according to individual farm protocol. Drugs and doses used for treatments were recorded for each case. Among all herds, 5 intramammary (IMM) antimicrobials (amoxicillin, hetacillin, pirlimycin, ceftiofur, and cephapirin) were used to treat cows for clinical mastitis. Of 712 cows with complete treatment data, 71.6% were treated with IMM ceftiofur either solely or combined with other antimicrobials (administered either IMM or systemically). Of cows experiencing severe symptoms of clinical mastitis, 43.8% received IMM treatment concurrent with systemic antimicrobials. Of all cows treated, 23.1% received an additional secondary treatment (either IMM, systemic, or both) because of perceived lack of response to the initial treatment. The majority of IMM treatments were administered to cows with a microbiological diagnosis of no growth (34.9%) or Escherichia coli (27.2%). Half of the cows experiencing cases caused by E. coli were treated using systemic antimicrobials in contrast to only 6.8% of cows experiencing cases caused by coagulase-negative staphylococci. In conflict with FDA regulations, which do not allow extra-label treatments using sulfonamides, a total of 22 cows from 8 farms were treated with systemic sulfadimethoxine either solely or in combination with oxytetracycline. Antimicrobial drugs were used on all herds and many cows received extra-label treatments. Great opportunity exists to improve mastitis therapy on large dairy herds, but use of more diagnostic methodologies is necessary to guide treatments. Farmers and veterinarians should work together to create protocols based on the herd needs considering reduced inappropriate and excessive use of antimicrobials.
authors.affiliation: Department of Dairy Science, University of Wisconsin, Madison 53706.
authors.forename: L
authors.initials: L
authors.lastname: Oliveira
authors.affiliation: Department of Dairy Science, University of Wisconsin, Madison 53706. Electronic address: plruegg@wisc.edu.
authors.forename: P L
authors.initials: PL
authors.lastname: Ruegg
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002417:Cattle; D002511:Cephalosporins / Q000627:therapeutic use; D002514:Cephapirin / Q000627:therapeutic use; D002981:Clindamycin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D007709:Klebsiella / Q000187:drug effects; D016015:Logistic Models; D008321:Mammary Glands, Animal / Q000382:microbiology / Q000473:pathology; D008414:Mastitis, Bovine / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology; D010118:Oxytetracycline / Q000627:therapeutic use; D010325:Pasteurella / Q000187:drug effects; D010406:Penicillins / Q000627:therapeutic use; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D014922:Wisconsin / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D002981:Clindamycin; D000658:Amoxicillin; C053503:ceftiofur; D002514:Cephapirin; C034093:pirlimycin; C100115:hetacillin; D010118:Oxytetracycline
keywords: antimicrobial; dairy; mastitis; treatment